Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drugs aid weight loss among type 2 diabetes patients

18.02.2005


Three commonly used drugs -- Prozac, Xenical and Meridia -- may help type 2 diabetes patients lose small amounts of weight, although long-term benefits are not clear, a new review of 22 studies suggests.



Prozac and Sarafem, known generically as fluoxetine, are most commonly prescribed as antidepressants. Xenical, the brand name for orlistat, blocks fat digestion in the intestines. Meridia, known generically as subtramine, is an appetite suppressant that works in the brain.

According to the systematic evidence review by Dr. Susan Norris of the U.S. Centers for Disease Control and Prevention and colleagues, patients taking fluoxetine had lost an average of 11 pounds (5.1 kilograms) 24 to 26 weeks after starting the therapy. Patients taking orlistat had lost an average of four and a half pounds (two kilograms) 12 to 57 weeks later, and those taking sibutramine had lost an average of 11 pounds 12 to 52 weeks later. “The magnitude of weight loss is modest, however, and the long-term health benefits remain unclear,” the review concludes.


Side effects of the therapies included oily bowel movements for those taking orlistat; sweating, tremors and drowsiness among fluoxetine users; and heart palpitations in some sibutramine patients.

Although the researchers acknowledge that long-term weight loss is “of paramount importance,” they say their review could help determine how weight loss drugs should fit into the overall picture of type 2 diabetes care. “For example, if weight loss can be demonstrated with drugs in the short term, pharmacotherapy may be combined with behavioral interventions for long-term weight control,” Norris says.

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Although a variety of other weight loss drugs exist, only 22 randomized controlled studies of fluoxetine, orlistat and sibutramine met the high standards set by the researchers for inclusion in the review.

Of the 22 studies reviewed, the drugs’ manufacturers paid for 18 of them and did not provide the reviewers with unpublished studies the companies had done on each of the included drugs, Norris says. Norris says there is only a small amount of data on other weight loss drugs and people with type 2 diabetes. For instance, the researchers did not find any good studies examining the effects of popular weight loss drugs like ephedra in diabetic patients.

Obesity has been closely linked with type 2 diabetes. In a 2000 study, 80 to 90 percent of people with type 2 diabetes are overweight. Obesity may also worsen problems associated with diabetes, including high blood sugar, high cholesterol and high blood pressure, say Norris and colleagues. Norris says people with diabetes who are also overweight may have a harder time losing weight than non-diabetics.

Insulin therapy itself might cause weight gain, Norris says. Keeping track of a complex series of treatments for diabetes, high cholesterol and high blood pressure “all complicate behavioral change aimed at weight reduction.”

Recommendations by the American Diabetes Association in 2002 say that weight loss drugs may be useful in treating obesity among type 2 diabetes patients, but also note that “these drugs work best in conjunction with lifestyle strategies” such as low fat diets and increased exercise.

Norris and colleagues say more research is needed to find out whether weight loss drugs work better when combined with diet and exercise changes.

“In general populations, drugs have been combined with various lifestyle interventions, but most [drug] trials include relatively weak lifestyle programs, perhaps in part to better reveal the medication effects,” Norris says.

1. Norris et al. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus (Review).The Cochrane Database of Systematic Reviews 2005, Issue 1

Susan Norris | EurekAlert!
Further information:
http://www.hbns.org

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>